TANDEM DIABETES CARE INC TNDM
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
-3.04
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.0B | -$204.7M | $546.0M | -$29.7M | $155.2M |
| 2024 | $940.2M | -$96.0M | $489.6M | $5.0M | $263.1M |
| 2023 | $747.7M | -$222.6M | $367.7M | -$58.6M | $313.6M |
| 2022 | $801.2M | -$94.6M | $413.0M | $16.4M | $439.9M |
| 2021 | $702.8M | $15.6M | $376.2M | $97.2M | $433.1M |
| 2020 | $498.8M | -$34.4M | $260.5M | -$2.7M | $366.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Gasser Elizabeth Anne | EVP, Chief Strategy Officer | 2026-06-02 | Gift | 7,160 | — |
| Gasser Elizabeth Anne | EVP, Chief Strategy Officer | 2026-06-02 | Gift | 7,160 | — |
| Allen Dick | 2026-05-21 | Option exercise | 8,759 | — | |
| Howell Peyton R | director | 2026-05-21 | Option exercise | 8,759 | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -3.04 (distress)
- Working capital / assets 0.426
- Retained earnings / assets -1.422
- EBIT / assets -0.213
- Equity / liabilities 0.214
Source: SEC EDGAR filings · CIK 0001438133 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.